Skip to main content

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease

Kahal, H.; Abouda, G.; Rigby, A. S.; Coady, A. M.; Kilpatrick, E. S.; Atkin, S. L.

Authors

H. Kahal

G. Abouda

A. S. Rigby

A. M. Coady

E. S. Kilpatrick

S. L. Atkin



Contributors

Alan Rigby
Other

Abstract

© 2013 John Wiley & Sons Ltd. Introduction: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis. Objective: To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis. Design: A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1.8 mg od. Results: Nineteen women with PCOS and 17 controls were recruited, age 32.8 ± 7.2 vs 33.5 ± 6.7 years and weight 100.9 ± 16.7 vs 99.3 ± 14.7 kg, respectively. At baseline, the PCOS group had higher testosterone 1.2 ± 0.3 vs 0.9 ± 0.3 nM (P = 0.01), HOMA-IR 5.1 ± 2.6 vs 3.5 ± 1.3 (P = 0.03), AST 22.4 ± 5.2 vs 18.8 ± 3.4 u/l (P = 0.04), PIIINP 4.4 ± 0.8 vs 3.5 ± 0.8 ug/ml (P = 0.01) and NAFLD seven (35%) vs none (P = 0.005), respectively. Twenty-five (69%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3.0 ± 4.2 kg (P = 0.01) and 3.8 ± 3.4 kg (P = 0.001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4.4 ± 0.8 vs 3.7 ± 0.9 ug/ml (P < 0.01), but not in controls 3.5 ± 0.8 vs 3.2 ± 0.7 ug/ml (P = 0. 08). Conclusions: Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD.

Journal Article Type Article
Publication Date 2014-10
Journal Clinical Endocrinology
Print ISSN 0300-0664
Electronic ISSN 1365-2265
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 81
Issue 4
Pages 523-528
APA6 Citation Kahal, H., Abouda, G., Rigby, A. S., Coady, A. M., Kilpatrick, E. S., & Atkin, S. L. (2014). Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clinical Endocrinology, 81(4), 523-528. doi:10.1111/cen.12369
DOI https://doi.org/10.1111/cen.12369
Keywords Endocrinology, Diabetes and Metabolism
Publisher URL https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.12369
;